Form 4: Q32 Bio Inc. CFO and President, Lee Kalowski, Reports Stock Option Grant
SEC Form 4 Filing
Lee Kalowski, CFO and President of Q32 Bio Inc., reports the acquisition of stock options for 161,323 shares of common stock.
Summary
- Lee Kalowski, the CFO and President of Q32 Bio Inc. (QTTB), filed a Form 4 with the SEC.
- The filing reports a transaction on March 25, 2024, where Kalowski acquired stock options for 161,323 shares.
- The exercise price of the stock options is $16.82.
- 25% of the shares underlying the option will vest on October 13, 2024, with the remaining shares vesting in 36 equal monthly installments, contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral positive.
Positives
- The grant of stock options to the CFO and President aligns their interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's long-term success.
Future Outlook
The vesting schedule suggests an expectation of continued service from the reporting person.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation strategy.
- The vesting schedule is typical, with initial vesting occurring around one year after the grant date, followed by monthly or quarterly installments.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of stock option grant. |
| 03/27/2024 | Date of Form 4 filing. |
| 10/12/2033 | Expiration date of the stock options. |
| 10/13/2024 | Initial vesting date for 25% of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.